Ivabradine sustained-release - Jiangsu Hengrui Medicine Co.Alternative Names: Ivabradine hemisulfate sustained-release tablets - Jiangsu HengRui Medicine
Latest Information Update: 24 Nov 2015
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Chronic heart failure